Speakers - Sachs Associates
Speakers - Sachs Associates
Speakers - Sachs Associates
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
CONTACTS<br />
Nick McCooke<br />
Chief Executive Officer<br />
Prof Nick La Thangue<br />
Chief Scientific Officer<br />
Prof David Kerr,<br />
Chief Medical Officer<br />
ADDRESS<br />
Magdalen Centre<br />
Oxford Science Park<br />
Oxford<br />
OX4 4GA<br />
TELEPHONE<br />
Office: +44 1865 784000<br />
Mobile: +44 7900 214268<br />
FAX<br />
+44 1235 861771<br />
EMAIL<br />
nick.mccooke@oxfordbio.com<br />
YEAR FOUNDED<br />
2011<br />
Oxford Cancer Biomarkers<br />
www.oxfordbio.com<br />
FINANCIAL SUMMARY<br />
$5M funding via equity investment from Quintiles<br />
COMPANY PROFILE<br />
Oxford Cancer Biomarkers (OCB) is a newly launched company developing tests that predict which cancer<br />
patients will respond favorably to existing and emerging cancer drugs allowing treatment to be tailored to<br />
individual patients.<br />
The company, which is a spin out from Oxford University, has a patent-protected and validated platform for<br />
discovering proteins that are novel chemosensitivity markers for specific drugs.<br />
OCB is developing its biomarkers tests both independently and in partnership with pharma and biotech<br />
companies.<br />
Setting the company apart from the crowd, OCB has already implemented a strategic relationship with Quintiles<br />
Inc that provides a route for accelerating its novel biomarkers into clinical trials, overcoming the inertia that can<br />
sometimes hamper the companion biomarker business model.<br />
The company has secured initial funding via a $5 million equity investment from Quintiles.<br />
OCB’s management team, led by Nick McCooke, former CEO of Solexa (the pioneer of next gen sequencing) and<br />
Pronota (protein biomarker diagnostic development), includes David Kerr, Professor of Cancer Medicine at the<br />
University of Oxford and a recent President of the European Society of Medical Oncology, and Nick La Thangue,<br />
Professor of Cancer Biology at the University of Oxford.<br />
MANAGEMENT<br />
Nick McCooke, CEO<br />
Nick is the former CEO of Pronota (developer of diagnostics based on novel protein biomarkers) and Solexa (the pioneer of next<br />
gen sequencing).<br />
David Kerr, CMO<br />
David is Professor of Cancer Medicine at the University of Oxford and a recent President of the European Society of Medical<br />
Oncology.<br />
Nick La Thangue, CSO<br />
Nick is Professor of Cancer Biology at the University of Oxford. His academic research is focused on the molecular<br />
mechanisms that give rise to the abnormal proliferation of tumour cells.<br />
t back :: next u<br />
WELCOME PHARMA LICENSING GROUPS<br />
SPEAKERS<br />
PRESENTING COMPANIES SUPPORTING ORGANISATIONS<br />
ORGANISERS
Change language